Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu

Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02793960
Recruitment Status : Completed
First Posted : June 8, 2016
Last Update Posted : June 16, 2020
Berg, LLC
Information provided by (Responsible Party):
Shasa Hu, University of Miami

Brief Summary:
This is a single-center study to investigate the effects of a topical cream on patients 12 years of age and older that have been diagnosed with epidermolysis bullosa.

Condition or disease Intervention/treatment Phase
Epidermolysis Bullosa Drug: topical BPM31510 3.0% Cream Phase 1

Detailed Description:

The trial will be conducted in patients with any form of Epidermolysis Bullosa (EB) with at least 1 active EB wound between 2.5 and 50 cm2 in size or up to 10% of the Body Surface Area. The investigators will identify an "index lesion" and other lesions for treatment An area of un-involved skin will also be treated with the study cream. This are will be used for testing by producing tiny blisters th so that the underlying tissue can be examined using a special microscope.

Patients will apply the study cream

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Therapeutic Effect of Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa
Actual Study Start Date : August 10, 2016
Actual Primary Completion Date : August 26, 2019
Actual Study Completion Date : August 26, 2019

Arm Intervention/treatment
Experimental: Topical BPM31510 3.0% Cream
Patients/ caregiver will apply topical BPM31510 3.0% cream from every other day to twice per week to wounded skin, and every day to a section of intact skin for up to 12 weeks.The area to be covered may not exceed 10% BSA inclusive of intact skin area, and other lesions.
Drug: topical BPM31510 3.0% Cream
Application of drug to lesions of epidermolysis bullosa

Primary Outcome Measures :
  1. Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment [ Time Frame: 16 weeks ]
    Analysis of laboratory values and/or Adverse events

Secondary Outcome Measures :
  1. Peak Plasma Concentration of BPM31510 [ Time Frame: Day 1, Day 3, week 8. ]
    Blood will be drawn pre-study drug application on Day 1 and post study drug application on Day 3 and Week 8

  2. Decrease in VAS Pain Scale questionnaire [ Time Frame: Baseline, 16 weeks ]
    Subject completed Questionnaire will assess the .pain at each visit.

  3. Change in Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) [ Time Frame: Baseline, 16 weeks ]
    The (EBDASI) be utilized by investigators to quantify wound healing and scarring at each visit.

  4. Change in the Lansky Performance Scale and the Children's Dermatology Life Quality Index [ Time Frame: Baseline, 16 weeks ]
    Subject completed questionnaires will be completed at each visit.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Male or female at least 12 years of age at the time of screening.
  2. Have primary, histologically confirmed EB verified by immunofluorescent antigenic mapping (EM) prior to starting application of study drug
  3. Have no other dermatological disease that may adversely impact wound healing.
  4. Willing to refrain from using topical creams or lotions other than the study drug to the designated areas during the treatment period and from washing the designated areas until the next application is done.
  5. Willing to refrain from exposure to excessive direct sunlight or ultraviolet light for the duration of the study.
  6. Laboratory values for the tests listed in the Study Schedule are within the local reference ranges as defined by the local laboratory, or "out of range" test results are clinically acceptable to the investigator. Acceptable "out of range" values are generally those within the patient's normal baseline levels due to concurrent medications or disease processes with the exception of INR and PT/APTT.
  7. Caregiver/guardian or patient is able to follow study required instructions and likely to complete all study visit requirements.
  8. Has a provided written informed consent by patient or a legal guardian, including consent for tissue to be examined and stored by the Department of Dermatology and Cutaneous Surgery. If the patient is between 12 and 17 years of age, assent must be given by the patient.
  9. Guardian has provided written consent to allow photographs of the target EB lesion(s) to be used as part of the study data and documentation.
  10. Females of childbearing potential must have a negative urine or serum pregnancy test at screening and be using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom, diaphragm, abstinence, or a monogamous relationship with a partner who has had a vasectomy).
  11. Have an INR value of 0.8-1.2 as well as normal PT/APTT.
  12. With at least 1 active EB wound between 2.5 and 50 cm2 in size on nonflexual surfaces

Exclusion Criteria:

  1. Received systemic therapy of living skin equivalent grafting in the past 30 days prior to baseline visit.
  2. Known or suspected systemic cancer such as lymphoma or leukemia.
  3. Evidence of dermatological disease or confounding skin condition in the treatment area, e.g., BCC, actinic keratosis, rosacea, psoriasis, atopic dermatitis, eczema, xerodermapigmentosa, or clinical evidence of infection.
  4. Concurrent disease or treatment that suppresses the immune system.
  5. Any chronic medical condition that, in the judgment of the investigator(s), can interfere with the performance of the study or would place the patient at undue risk.
  6. Known sensitivity to any of the ingredients in the trial medication (BPM31510 3.0% Cream
  7. Treatment with any systemic immunomodulators or immunosuppressants within the 2 months prior to enrollment, for a duration longer than 2 weeks.
  8. Use of any topical immunomodulators such as topical tacrolimus.
  9. Use of systemic or topical steroids within 30 days prior to enrollment is excluded (inhaled steroids and ophthalmic drops containing steroids are allowed).
  10. Any elective or non-elective surgery other than biopsy for EB, or surgeries for the treatment of sequelae of EB such as g-tube placement or esophageal dilatation within 4 weeks prior to enrollment during the study. Elective procedures pertaining to skin graft will not be allowed at any time.
  11. Current enrollment in an investigational drug or device study or participation in such a study within 4 weeks of enrollment.
  12. In the investigator's opinion, evidence of unwillingness or inability of the patient or caregiver to follow the restrictions and complete the study.
  13. Has any clotting disorder, or is being treated with any anticoagulant.
  14. Any abnormal laboratory value or concurrent illness that, in the opinion of the investigator, should preclude the patient's participation in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02793960

Layout table for location information
United States, Florida
University of Miami Department of Dermatology
Miami, Florida, United States, 33136
Sponsors and Collaborators
Shasa Hu
Berg, LLC
Layout table for additonal information
Responsible Party: Shasa Hu, Professor, University of Miami Identifier: NCT02793960    
Other Study ID Numbers: 20151103
First Posted: June 8, 2016    Key Record Dates
Last Update Posted: June 16, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Epidermolysis Bullosa
Skin Abnormalities
Congenital Abnormalities
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases
Skin Diseases, Vesiculobullous